Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT: The poly(ADP-ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe. We provide a population pharmacokinetic model for this combination in patients with mCRPC unselected for HRR deficiencies from TALAPRO-2 (NCT03395197). The pooled dataset included 811 patients treated with enzalutamide plus either talazoparib or placebo. The final enzalutamide model was a two-compartment model with first-order absorption and inter-individual variability (IIV) on apparent clearance (CL_e/F_e) and apparent central volume of d

SUBMITTER: Hadigol M 

PROVIDER: S-EPMC12934543 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature